Clinical Trials Logo

Plasmapheresis clinical trials

View clinical trials related to Plasmapheresis.

Filter by:
  • None
  • Page 1

NCT ID: NCT05815615 Completed - Inflammation Clinical Trials

Plasmapheresis: a Multi-modal Approach

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Only very few studies have prospectively looked at the effect of repeated intensive plasma donation. In collaboration with the Rode Kruis Vlaanderen, we have recently found that repeated whole blood donation with a 3-month interval in between induced a drop in markers for iron status, which worsened with the number of donations. The repetition effect of the donations, whether whole blood or plasma, can be different from the effects measured after one single donation. It is therefore critical to test and document this repetitive effect to build trustable and valid guidelines concerning repetitive plasma donation.

NCT ID: NCT05562960 Recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP

PALATIN
Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Patient with amyotrophic lateral sclerosis (ALS) having anti-NRIP autoantibody showed titer-dependent detrimental Effects. Plasmapheresis might benefit this subgroup of patients via removal of anti-NRIP autoantibody

NCT ID: NCT05004220 Completed - Aging Clinical Trials

Effects of Plasmapheresis on Aging Biomarkers

Start date: April 6, 2021
Phase:
Study type: Observational

The aim of the study is to evaluate the effect of plasmapheresis (repeated plasma withdrawals) on selected health indicators (hematological, biochemical, immunological and indicators of biological age) of plasma donors.

NCT ID: NCT03965559 Completed - Clinical trials for Kidney Transplant Rejection

The Efficacy of Plasmapheresis and Double Filtration Plasmapheresis (DFPP) in Kidney Transplant

Start date: November 1, 2015
Phase:
Study type: Observational

At present, the number of end-stage kidney disease patients is increasing. Kidney transplant surgery is one of the treatments that give patients a better survival rate than hemodialysis or abdominal dialysis. In Thailand, there were 5,729 kidney transplant patients or 88.9 cases per million population in 2012. Among this number, 465 were new surgical patients or 7.2 cases per million population. From the year 2007-2012, the survival rate of the kidney donor from living donor kidney transplant (LDKT) was 98.5 percent and 93.3 percent at 1 and 5 years, respectively. The most common cause of graft loss was chronic rejection by 33% of all graft loss. However, 16.1 percent were unknown reasons for graft loss. The research question is "In patients with kidney transplantation who suspected graft rejection" Is it true that doing plasmapheresis or DFPP is no different. The researcher therefore conducted a comparative study. Is plasmapheresis or DFPP effective or different side effects?

NCT ID: NCT00203281 Withdrawn - Clinical trials for Kidney Transplantation

Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis

Start date: February 2003
Phase: Phase 4
Study type: Observational

Based on the limited amount of experience with plasmapheresis and CytoGam concomitant use, the researchers seek to evaluate the pharmacokinetics (drug absorption, distribution, and elimination) of this therapy. The researchers are also interested in evaluating the pharmacokinetics of the various immunosuppressant medications that patients will receive such as tacrolimus, mycophenolate mofetil and daclizumab.

NCT ID: NCT00001349 Terminated - Plasmapheresis Clinical Trials

Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies

Start date: March 23, 1993
Phase:
Study type: Observational

This study will collect blood plasma and white blood cells for laboratory research using a procedure called apheresis. Apheresis is a method of collecting larger quantities of certain blood components than can safely be collected through a simple blood draw. Patients 7 years of age and older with a parasitic infection or condition associated with a parasitic infection (i.e., elevated levels of IgE antibodies or of a type of white cell called eosinophils) who are currently enrolled in a NIH clinical research protocol may be eligible for this study. Relatives of patients and normal healthy volunteers will also be enrolled. Candidates will have a medical history, physical examination and blood tests. Individuals weighing less than 25 kilograms (55 pounds) may not participate. Participants will undergo one of the following two apheresis procedures: - Automated pheresis Whole blood is drawn through a needle placed in an arm vein and circulated through a cell separator machine. The plasma (liquid part of the blood) and white cells are extracted, and the red cells are re-infused into the donor through a needle in the other arm. The procedure takes 1 to 2 hours. - Manual pheresis Whole blood is drawn through a needle placed in an arm vein and circulated through the cell separator machine. The red blood cells are separated from the rest of the blood and returned to the donor through the same needle. Usually only one needle stick is required and the procedure takes from 30 to 45 minutes. This method is used only in individuals who weigh less than 35 kg (77 pounds).